nodes	percent_of_prediction	percent_of_DWPC	metapath
Methocarbamol—Carvedilol—HIF1A—pancreatic cancer	0.0368	0.713	CrCbGaD
Methocarbamol—Nystagmus—Fluorouracil—pancreatic cancer	0.0187	0.0197	CcSEcCtD
Methocarbamol—Lightheadedness—Tamoxifen—pancreatic cancer	0.0177	0.0187	CcSEcCtD
Methocarbamol—Injury—Tamoxifen—pancreatic cancer	0.0156	0.0165	CcSEcCtD
Methocarbamol—Carvedilol—VEGFA—pancreatic cancer	0.0148	0.287	CrCbGaD
Methocarbamol—Nasal congestion—Sunitinib—pancreatic cancer	0.0135	0.0142	CcSEcCtD
Methocarbamol—Thrombophlebitis—Irinotecan—pancreatic cancer	0.0117	0.0123	CcSEcCtD
Methocarbamol—Thrombophlebitis—Fluorouracil—pancreatic cancer	0.0112	0.0118	CcSEcCtD
Methocarbamol—Injury—Irinotecan—pancreatic cancer	0.011	0.0116	CcSEcCtD
Methocarbamol—Conjunctivitis—Erlotinib—pancreatic cancer	0.0106	0.0112	CcSEcCtD
Methocarbamol—Amnesia—Fluorouracil—pancreatic cancer	0.0103	0.0109	CcSEcCtD
Methocarbamol—Flushing—Tamoxifen—pancreatic cancer	0.00922	0.00972	CcSEcCtD
Methocarbamol—Nystagmus—Epirubicin—pancreatic cancer	0.00911	0.00961	CcSEcCtD
Methocarbamol—Bradycardia—Sunitinib—pancreatic cancer	0.00866	0.00913	CcSEcCtD
Methocarbamol—Lightheadedness—Docetaxel—pancreatic cancer	0.00863	0.0091	CcSEcCtD
Methocarbamol—Dysgeusia—Tamoxifen—pancreatic cancer	0.00847	0.00893	CcSEcCtD
Methocarbamol—Nystagmus—Doxorubicin—pancreatic cancer	0.00843	0.00889	CcSEcCtD
Methocarbamol—Thrombophlebitis—Docetaxel—pancreatic cancer	0.00809	0.00853	CcSEcCtD
Methocarbamol—Angioedema—Tamoxifen—pancreatic cancer	0.0079	0.00833	CcSEcCtD
Methocarbamol—Flushing—Sunitinib—pancreatic cancer	0.0079	0.00833	CcSEcCtD
Methocarbamol—Leukopenia—Tamoxifen—pancreatic cancer	0.00774	0.00816	CcSEcCtD
Methocarbamol—Syncope—Erlotinib—pancreatic cancer	0.00767	0.00809	CcSEcCtD
Methocarbamol—Jaundice—Irinotecan—pancreatic cancer	0.00761	0.00803	CcSEcCtD
Methocarbamol—Loss of consciousness—Erlotinib—pancreatic cancer	0.00752	0.00793	CcSEcCtD
Methocarbamol—Jaundice cholestatic—Epirubicin—pancreatic cancer	0.00741	0.00781	CcSEcCtD
Methocarbamol—Conjunctivitis—Fluorouracil—pancreatic cancer	0.00727	0.00766	CcSEcCtD
Methocarbamol—Dysgeusia—Sunitinib—pancreatic cancer	0.00725	0.00765	CcSEcCtD
Methocarbamol—Bradycardia—Irinotecan—pancreatic cancer	0.00714	0.00752	CcSEcCtD
Methocarbamol—Shock—Erlotinib—pancreatic cancer	0.00687	0.00724	CcSEcCtD
Methocarbamol—Jaundice cholestatic—Doxorubicin—pancreatic cancer	0.00685	0.00723	CcSEcCtD
Methocarbamol—Angioedema—Sunitinib—pancreatic cancer	0.00677	0.00714	CcSEcCtD
Methocarbamol—Leukopenia—Sunitinib—pancreatic cancer	0.00663	0.00699	CcSEcCtD
Methocarbamol—Coordination abnormal—Epirubicin—pancreatic cancer	0.00663	0.00699	CcSEcCtD
Methocarbamol—Flushing—Irinotecan—pancreatic cancer	0.00651	0.00686	CcSEcCtD
Methocarbamol—Convulsion—Sunitinib—pancreatic cancer	0.00642	0.00677	CcSEcCtD
Methocarbamol—Insomnia—Tamoxifen—pancreatic cancer	0.00638	0.00673	CcSEcCtD
Methocarbamol—Insomnia—Erlotinib—pancreatic cancer	0.00632	0.00666	CcSEcCtD
Methocarbamol—Dyspepsia—Tamoxifen—pancreatic cancer	0.00621	0.00655	CcSEcCtD
Methocarbamol—Dyspepsia—Erlotinib—pancreatic cancer	0.00615	0.00648	CcSEcCtD
Methocarbamol—Coordination abnormal—Doxorubicin—pancreatic cancer	0.00613	0.00647	CcSEcCtD
Methocarbamol—Pain—Tamoxifen—pancreatic cancer	0.00604	0.00636	CcSEcCtD
Methocarbamol—Pain—Erlotinib—pancreatic cancer	0.00597	0.0063	CcSEcCtD
Methocarbamol—Shock—Sunitinib—pancreatic cancer	0.00595	0.00627	CcSEcCtD
Methocarbamol—Urticaria—Tamoxifen—pancreatic cancer	0.00561	0.00591	CcSEcCtD
Methocarbamol—Body temperature increased—Erlotinib—pancreatic cancer	0.00552	0.00582	CcSEcCtD
Methocarbamol—Vision blurred—Fluorouracil—pancreatic cancer	0.00551	0.00581	CcSEcCtD
Methocarbamol—Vertigo—Irinotecan—pancreatic cancer	0.00548	0.00578	CcSEcCtD
Methocarbamol—Syncope—Irinotecan—pancreatic cancer	0.00547	0.00577	CcSEcCtD
Methocarbamol—Insomnia—Sunitinib—pancreatic cancer	0.00547	0.00577	CcSEcCtD
Methocarbamol—Leukopenia—Irinotecan—pancreatic cancer	0.00546	0.00576	CcSEcCtD
Methocarbamol—Thrombophlebitis—Epirubicin—pancreatic cancer	0.00546	0.00575	CcSEcCtD
Methocarbamol—Loss of consciousness—Irinotecan—pancreatic cancer	0.00536	0.00565	CcSEcCtD
Methocarbamol—Dyspepsia—Sunitinib—pancreatic cancer	0.00532	0.00561	CcSEcCtD
Methocarbamol—Leukopenia—Gemcitabine—pancreatic cancer	0.00532	0.00561	CcSEcCtD
Methocarbamol—Jaundice—Docetaxel—pancreatic cancer	0.00526	0.00555	CcSEcCtD
Methocarbamol—Conjunctivitis—Docetaxel—pancreatic cancer	0.00525	0.00553	CcSEcCtD
Methocarbamol—Leukopenia—Fluorouracil—pancreatic cancer	0.00523	0.00552	CcSEcCtD
Methocarbamol—Hypersensitivity—Tamoxifen—pancreatic cancer	0.0052	0.00548	CcSEcCtD
Methocarbamol—Pain—Sunitinib—pancreatic cancer	0.00517	0.00545	CcSEcCtD
Methocarbamol—Convulsion—Fluorouracil—pancreatic cancer	0.00506	0.00534	CcSEcCtD
Methocarbamol—Thrombophlebitis—Doxorubicin—pancreatic cancer	0.00505	0.00532	CcSEcCtD
Methocarbamol—Confusional state—Irinotecan—pancreatic cancer	0.00502	0.00529	CcSEcCtD
Methocarbamol—Pruritus—Tamoxifen—pancreatic cancer	0.00499	0.00527	CcSEcCtD
Methocarbamol—Anaphylactic shock—Irinotecan—pancreatic cancer	0.00498	0.00525	CcSEcCtD
Methocarbamol—Pruritus—Erlotinib—pancreatic cancer	0.00494	0.00521	CcSEcCtD
Methocarbamol—Shock—Irinotecan—pancreatic cancer	0.0049	0.00517	CcSEcCtD
Methocarbamol—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.00485	0.00511	CcSEcCtD
Methocarbamol—Confusional state—Fluorouracil—pancreatic cancer	0.00481	0.00507	CcSEcCtD
Methocarbamol—Body temperature increased—Sunitinib—pancreatic cancer	0.00478	0.00504	CcSEcCtD
Methocarbamol—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.00477	0.00503	CcSEcCtD
Methocarbamol—Diplopia—Epirubicin—pancreatic cancer	0.00472	0.00498	CcSEcCtD
Methocarbamol—Dizziness—Tamoxifen—pancreatic cancer	0.00467	0.00492	CcSEcCtD
Methocarbamol—Hypotension—Irinotecan—pancreatic cancer	0.00465	0.00491	CcSEcCtD
Methocarbamol—Dizziness—Erlotinib—pancreatic cancer	0.00462	0.00487	CcSEcCtD
Methocarbamol—Hypotension—Gemcitabine—pancreatic cancer	0.00453	0.00478	CcSEcCtD
Methocarbamol—Insomnia—Irinotecan—pancreatic cancer	0.0045	0.00475	CcSEcCtD
Methocarbamol—Flushing—Docetaxel—pancreatic cancer	0.0045	0.00474	CcSEcCtD
Methocarbamol—Vomiting—Tamoxifen—pancreatic cancer	0.00449	0.00473	CcSEcCtD
Methocarbamol—Hypotension—Fluorouracil—pancreatic cancer	0.00446	0.0047	CcSEcCtD
Methocarbamol—Hypersensitivity—Sunitinib—pancreatic cancer	0.00445	0.0047	CcSEcCtD
Methocarbamol—Rash—Tamoxifen—pancreatic cancer	0.00445	0.00469	CcSEcCtD
Methocarbamol—Dermatitis—Tamoxifen—pancreatic cancer	0.00445	0.00469	CcSEcCtD
Methocarbamol—Vomiting—Erlotinib—pancreatic cancer	0.00444	0.00468	CcSEcCtD
Methocarbamol—Somnolence—Irinotecan—pancreatic cancer	0.00443	0.00467	CcSEcCtD
Methocarbamol—Headache—Tamoxifen—pancreatic cancer	0.00442	0.00466	CcSEcCtD
Methocarbamol—Rash—Erlotinib—pancreatic cancer	0.0044	0.00464	CcSEcCtD
Methocarbamol—Dermatitis—Erlotinib—pancreatic cancer	0.0044	0.00464	CcSEcCtD
Methocarbamol—Insomnia—Gemcitabine—pancreatic cancer	0.00439	0.00463	CcSEcCtD
Methocarbamol—Dyspepsia—Irinotecan—pancreatic cancer	0.00438	0.00462	CcSEcCtD
Methocarbamol—Headache—Erlotinib—pancreatic cancer	0.00437	0.00461	CcSEcCtD
Methocarbamol—Diplopia—Doxorubicin—pancreatic cancer	0.00437	0.00461	CcSEcCtD
Methocarbamol—Insomnia—Fluorouracil—pancreatic cancer	0.00431	0.00455	CcSEcCtD
Methocarbamol—Somnolence—Gemcitabine—pancreatic cancer	0.00431	0.00455	CcSEcCtD
Methocarbamol—Pruritus—Sunitinib—pancreatic cancer	0.00428	0.00451	CcSEcCtD
Methocarbamol—Pain—Irinotecan—pancreatic cancer	0.00426	0.00449	CcSEcCtD
Methocarbamol—Somnolence—Fluorouracil—pancreatic cancer	0.00424	0.00447	CcSEcCtD
Methocarbamol—Dyspepsia—Fluorouracil—pancreatic cancer	0.0042	0.00443	CcSEcCtD
Methocarbamol—Nausea—Tamoxifen—pancreatic cancer	0.00419	0.00442	CcSEcCtD
Methocarbamol—Pain—Gemcitabine—pancreatic cancer	0.00415	0.00437	CcSEcCtD
Methocarbamol—Nausea—Erlotinib—pancreatic cancer	0.00415	0.00437	CcSEcCtD
Methocarbamol—Dysgeusia—Docetaxel—pancreatic cancer	0.00413	0.00436	CcSEcCtD
Methocarbamol—Feeling abnormal—Irinotecan—pancreatic cancer	0.0041	0.00433	CcSEcCtD
Methocarbamol—Pain—Fluorouracil—pancreatic cancer	0.00408	0.0043	CcSEcCtD
Methocarbamol—Dizziness—Sunitinib—pancreatic cancer	0.004	0.00422	CcSEcCtD
Methocarbamol—Feeling abnormal—Gemcitabine—pancreatic cancer	0.004	0.00422	CcSEcCtD
Methocarbamol—Body temperature increased—Irinotecan—pancreatic cancer	0.00394	0.00415	CcSEcCtD
Methocarbamol—Feeling abnormal—Fluorouracil—pancreatic cancer	0.00393	0.00414	CcSEcCtD
Methocarbamol—Vomiting—Sunitinib—pancreatic cancer	0.00384	0.00405	CcSEcCtD
Methocarbamol—Body temperature increased—Gemcitabine—pancreatic cancer	0.00383	0.00404	CcSEcCtD
Methocarbamol—Rash—Sunitinib—pancreatic cancer	0.00381	0.00402	CcSEcCtD
Methocarbamol—Dermatitis—Sunitinib—pancreatic cancer	0.00381	0.00402	CcSEcCtD
Methocarbamol—Urticaria—Fluorouracil—pancreatic cancer	0.00379	0.004	CcSEcCtD
Methocarbamol—Headache—Sunitinib—pancreatic cancer	0.00379	0.00399	CcSEcCtD
Methocarbamol—Syncope—Docetaxel—pancreatic cancer	0.00378	0.00399	CcSEcCtD
Methocarbamol—Leukopenia—Docetaxel—pancreatic cancer	0.00378	0.00398	CcSEcCtD
Methocarbamol—Body temperature increased—Fluorouracil—pancreatic cancer	0.00377	0.00398	CcSEcCtD
Methocarbamol—Loss of consciousness—Docetaxel—pancreatic cancer	0.00371	0.00391	CcSEcCtD
Methocarbamol—Hypersensitivity—Irinotecan—pancreatic cancer	0.00367	0.00387	CcSEcCtD
Methocarbamol—Convulsion—Docetaxel—pancreatic cancer	0.00365	0.00385	CcSEcCtD
Methocarbamol—Drowsiness—Epirubicin—pancreatic cancer	0.00364	0.00384	CcSEcCtD
Methocarbamol—Nausea—Sunitinib—pancreatic cancer	0.00359	0.00379	CcSEcCtD
Methocarbamol—Jaundice—Epirubicin—pancreatic cancer	0.00355	0.00374	CcSEcCtD
Methocarbamol—Conjunctivitis—Epirubicin—pancreatic cancer	0.00354	0.00373	CcSEcCtD
Methocarbamol—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00351	0.00371	CcSEcCtD
Methocarbamol—Confusional state—Docetaxel—pancreatic cancer	0.00347	0.00366	CcSEcCtD
Methocarbamol—Anaphylactic shock—Docetaxel—pancreatic cancer	0.00344	0.00363	CcSEcCtD
Methocarbamol—Pruritus—Gemcitabine—pancreatic cancer	0.00343	0.00362	CcSEcCtD
Methocarbamol—Shock—Docetaxel—pancreatic cancer	0.00339	0.00357	CcSEcCtD
Methocarbamol—Pruritus—Fluorouracil—pancreatic cancer	0.00337	0.00356	CcSEcCtD
Methocarbamol—Drowsiness—Doxorubicin—pancreatic cancer	0.00337	0.00355	CcSEcCtD
Methocarbamol—Bradycardia—Epirubicin—pancreatic cancer	0.00333	0.00351	CcSEcCtD
Methocarbamol—Dizziness—Irinotecan—pancreatic cancer	0.00329	0.00347	CcSEcCtD
Methocarbamol—Jaundice—Doxorubicin—pancreatic cancer	0.00328	0.00346	CcSEcCtD
Methocarbamol—Conjunctivitis—Doxorubicin—pancreatic cancer	0.00327	0.00345	CcSEcCtD
Methocarbamol—Hypotension—Docetaxel—pancreatic cancer	0.00322	0.00339	CcSEcCtD
Methocarbamol—Vomiting—Irinotecan—pancreatic cancer	0.00317	0.00334	CcSEcCtD
Methocarbamol—Dizziness—Fluorouracil—pancreatic cancer	0.00315	0.00333	CcSEcCtD
Methocarbamol—Rash—Irinotecan—pancreatic cancer	0.00314	0.00331	CcSEcCtD
Methocarbamol—Dermatitis—Irinotecan—pancreatic cancer	0.00314	0.00331	CcSEcCtD
Methocarbamol—Headache—Irinotecan—pancreatic cancer	0.00312	0.00329	CcSEcCtD
Methocarbamol—Insomnia—Docetaxel—pancreatic cancer	0.00311	0.00328	CcSEcCtD
Methocarbamol—Vomiting—Gemcitabine—pancreatic cancer	0.00308	0.00325	CcSEcCtD
Methocarbamol—Bradycardia—Doxorubicin—pancreatic cancer	0.00308	0.00325	CcSEcCtD
Methocarbamol—Somnolence—Docetaxel—pancreatic cancer	0.00306	0.00323	CcSEcCtD
Methocarbamol—Rash—Gemcitabine—pancreatic cancer	0.00306	0.00323	CcSEcCtD
Methocarbamol—Dermatitis—Gemcitabine—pancreatic cancer	0.00306	0.00322	CcSEcCtD
Methocarbamol—Headache—Gemcitabine—pancreatic cancer	0.00304	0.0032	CcSEcCtD
Methocarbamol—Flushing—Epirubicin—pancreatic cancer	0.00303	0.0032	CcSEcCtD
Methocarbamol—Vomiting—Fluorouracil—pancreatic cancer	0.00303	0.0032	CcSEcCtD
Methocarbamol—Dyspepsia—Docetaxel—pancreatic cancer	0.00303	0.0032	CcSEcCtD
Methocarbamol—Rash—Fluorouracil—pancreatic cancer	0.00301	0.00317	CcSEcCtD
Methocarbamol—Dermatitis—Fluorouracil—pancreatic cancer	0.003	0.00317	CcSEcCtD
Methocarbamol—Headache—Fluorouracil—pancreatic cancer	0.00299	0.00315	CcSEcCtD
Methocarbamol—Nausea—Irinotecan—pancreatic cancer	0.00296	0.00312	CcSEcCtD
Methocarbamol—Pain—Docetaxel—pancreatic cancer	0.00294	0.0031	CcSEcCtD
Methocarbamol—Nausea—Gemcitabine—pancreatic cancer	0.00288	0.00304	CcSEcCtD
Methocarbamol—Feeling abnormal—Docetaxel—pancreatic cancer	0.00284	0.00299	CcSEcCtD
Methocarbamol—Nausea—Fluorouracil—pancreatic cancer	0.00283	0.00299	CcSEcCtD
Methocarbamol—Flushing—Doxorubicin—pancreatic cancer	0.00281	0.00296	CcSEcCtD
Methocarbamol—Dysgeusia—Epirubicin—pancreatic cancer	0.00279	0.00294	CcSEcCtD
Methocarbamol—Body temperature increased—Docetaxel—pancreatic cancer	0.00272	0.00287	CcSEcCtD
Methocarbamol—Vision blurred—Epirubicin—pancreatic cancer	0.00268	0.00283	CcSEcCtD
Methocarbamol—Dysgeusia—Doxorubicin—pancreatic cancer	0.00258	0.00272	CcSEcCtD
Methocarbamol—Vertigo—Epirubicin—pancreatic cancer	0.00256	0.0027	CcSEcCtD
Methocarbamol—Syncope—Epirubicin—pancreatic cancer	0.00255	0.00269	CcSEcCtD
Methocarbamol—Leukopenia—Epirubicin—pancreatic cancer	0.00255	0.00269	CcSEcCtD
Methocarbamol—Hypersensitivity—Docetaxel—pancreatic cancer	0.00254	0.00267	CcSEcCtD
Methocarbamol—Loss of consciousness—Epirubicin—pancreatic cancer	0.0025	0.00264	CcSEcCtD
Methocarbamol—Vision blurred—Doxorubicin—pancreatic cancer	0.00248	0.00262	CcSEcCtD
Methocarbamol—Convulsion—Epirubicin—pancreatic cancer	0.00246	0.0026	CcSEcCtD
Methocarbamol—Pruritus—Docetaxel—pancreatic cancer	0.00244	0.00257	CcSEcCtD
Methocarbamol—Vertigo—Doxorubicin—pancreatic cancer	0.00237	0.00249	CcSEcCtD
Methocarbamol—Syncope—Doxorubicin—pancreatic cancer	0.00236	0.00249	CcSEcCtD
Methocarbamol—Leukopenia—Doxorubicin—pancreatic cancer	0.00236	0.00248	CcSEcCtD
Methocarbamol—Confusional state—Epirubicin—pancreatic cancer	0.00234	0.00247	CcSEcCtD
Methocarbamol—Anaphylactic shock—Epirubicin—pancreatic cancer	0.00232	0.00245	CcSEcCtD
Methocarbamol—Loss of consciousness—Doxorubicin—pancreatic cancer	0.00231	0.00244	CcSEcCtD
Methocarbamol—Shock—Epirubicin—pancreatic cancer	0.00228	0.00241	CcSEcCtD
Methocarbamol—Convulsion—Doxorubicin—pancreatic cancer	0.00228	0.0024	CcSEcCtD
Methocarbamol—Dizziness—Docetaxel—pancreatic cancer	0.00228	0.0024	CcSEcCtD
Methocarbamol—Vomiting—Docetaxel—pancreatic cancer	0.00219	0.00231	CcSEcCtD
Methocarbamol—Rash—Docetaxel—pancreatic cancer	0.00217	0.00229	CcSEcCtD
Methocarbamol—Hypotension—Epirubicin—pancreatic cancer	0.00217	0.00229	CcSEcCtD
Methocarbamol—Dermatitis—Docetaxel—pancreatic cancer	0.00217	0.00229	CcSEcCtD
Methocarbamol—Confusional state—Doxorubicin—pancreatic cancer	0.00217	0.00228	CcSEcCtD
Methocarbamol—Headache—Docetaxel—pancreatic cancer	0.00216	0.00227	CcSEcCtD
Methocarbamol—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.00215	0.00227	CcSEcCtD
Methocarbamol—Shock—Doxorubicin—pancreatic cancer	0.00211	0.00223	CcSEcCtD
Methocarbamol—Insomnia—Epirubicin—pancreatic cancer	0.0021	0.00221	CcSEcCtD
Methocarbamol—Somnolence—Epirubicin—pancreatic cancer	0.00206	0.00218	CcSEcCtD
Methocarbamol—Nausea—Docetaxel—pancreatic cancer	0.00204	0.00216	CcSEcCtD
Methocarbamol—Dyspepsia—Epirubicin—pancreatic cancer	0.00204	0.00216	CcSEcCtD
Methocarbamol—Hypotension—Doxorubicin—pancreatic cancer	0.00201	0.00212	CcSEcCtD
Methocarbamol—Pain—Epirubicin—pancreatic cancer	0.00199	0.00209	CcSEcCtD
Methocarbamol—Insomnia—Doxorubicin—pancreatic cancer	0.00194	0.00205	CcSEcCtD
Methocarbamol—Feeling abnormal—Epirubicin—pancreatic cancer	0.00191	0.00202	CcSEcCtD
Methocarbamol—Somnolence—Doxorubicin—pancreatic cancer	0.00191	0.00201	CcSEcCtD
Methocarbamol—Dyspepsia—Doxorubicin—pancreatic cancer	0.00189	0.00199	CcSEcCtD
Methocarbamol—Urticaria—Epirubicin—pancreatic cancer	0.00184	0.00194	CcSEcCtD
Methocarbamol—Pain—Doxorubicin—pancreatic cancer	0.00184	0.00194	CcSEcCtD
Methocarbamol—Body temperature increased—Epirubicin—pancreatic cancer	0.00184	0.00194	CcSEcCtD
Methocarbamol—Feeling abnormal—Doxorubicin—pancreatic cancer	0.00177	0.00187	CcSEcCtD
Methocarbamol—Hypersensitivity—Epirubicin—pancreatic cancer	0.00171	0.0018	CcSEcCtD
Methocarbamol—Urticaria—Doxorubicin—pancreatic cancer	0.00171	0.0018	CcSEcCtD
Methocarbamol—Body temperature increased—Doxorubicin—pancreatic cancer	0.0017	0.00179	CcSEcCtD
Methocarbamol—Pruritus—Epirubicin—pancreatic cancer	0.00164	0.00173	CcSEcCtD
Methocarbamol—Hypersensitivity—Doxorubicin—pancreatic cancer	0.00158	0.00167	CcSEcCtD
Methocarbamol—Dizziness—Epirubicin—pancreatic cancer	0.00154	0.00162	CcSEcCtD
Methocarbamol—Pruritus—Doxorubicin—pancreatic cancer	0.00152	0.0016	CcSEcCtD
Methocarbamol—Vomiting—Epirubicin—pancreatic cancer	0.00148	0.00156	CcSEcCtD
Methocarbamol—Rash—Epirubicin—pancreatic cancer	0.00146	0.00154	CcSEcCtD
Methocarbamol—Dermatitis—Epirubicin—pancreatic cancer	0.00146	0.00154	CcSEcCtD
Methocarbamol—Headache—Epirubicin—pancreatic cancer	0.00145	0.00153	CcSEcCtD
Methocarbamol—Dizziness—Doxorubicin—pancreatic cancer	0.00142	0.0015	CcSEcCtD
Methocarbamol—Nausea—Epirubicin—pancreatic cancer	0.00138	0.00145	CcSEcCtD
Methocarbamol—Vomiting—Doxorubicin—pancreatic cancer	0.00137	0.00144	CcSEcCtD
Methocarbamol—Rash—Doxorubicin—pancreatic cancer	0.00135	0.00143	CcSEcCtD
Methocarbamol—Dermatitis—Doxorubicin—pancreatic cancer	0.00135	0.00143	CcSEcCtD
Methocarbamol—Headache—Doxorubicin—pancreatic cancer	0.00135	0.00142	CcSEcCtD
Methocarbamol—Nausea—Doxorubicin—pancreatic cancer	0.00128	0.00135	CcSEcCtD
